1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Noven Pharmaceuticals, Inc. – Product Pipeline Review – 2013

Noven Pharmaceuticals, Inc. – Product Pipeline Review – 2013

  • April 2013
  • -
  • Global Markets Direct
  • -
  • 30 pages

Noven Pharmaceuticals, Inc. – Product Pipeline Review – 2013

Summary

Global Market Direct’s pharmaceuticals report, “Noven Pharmaceuticals, Inc. - Product Pipeline Review - 2013” provides data on the Noven Pharmaceuticals, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Noven Pharmaceuticals, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Noven Pharmaceuticals, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Noven Pharmaceuticals, Inc. - Brief Noven Pharmaceuticals, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Noven Pharmaceuticals, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Noven Pharmaceuticals, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Noven Pharmaceuticals, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Noven Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Noven Pharmaceuticals, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Noven Pharmaceuticals, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Noven Pharmaceuticals, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Noven Pharmaceuticals, Inc. and identify potential opportunities in those areas.

Table Of Contents

Noven Pharmaceuticals, Inc. - Product Pipeline Review - 2013
Table of Contents

Table of Contents 2
List of Tables 3
List of Figures 3
Noven Pharmaceuticals, Inc. Snapshot 4
Noven Pharmaceuticals, Inc. Overview 4
Key Information 4
Key Facts 4
Noven Pharmaceuticals, Inc. - Research and Development Overview 5
Key Therapeutic Areas 5
Noven Pharmaceuticals, Inc. - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
Noven Pharmaceuticals, Inc. - Pipeline Products Glance 9
Noven Pharmaceuticals, Inc. - Late Stage Pipeline 9
Registration Filed Products/Combination Treatment Modalities 9
Noven Pharmaceuticals, Inc. - Early Stage Pipeline Products 10
Pre-Clinical Products/Combination Treatment Modalities 10
Noven Pharmaceuticals, Inc. - Drug Profiles 11
paroxetine mesylate 11
Product Description 11
Mechanism of Action 11
RandD Progress 11
Noven Pharmaceuticals, Inc. - Pipeline Products by Route of Administration 13
Noven Pharmaceuticals, Inc. - Pipeline Products By Mechanism of Action 14
Noven Pharmaceuticals, Inc. - Recent Pipeline Updates 15
Noven Pharmaceuticals, Inc. - Dormant Projects 16
Noven Pharmaceuticals, Inc. - Locations And Subsidiaries 17
Head Office 17
Other Locations and Subsidiaries 17
Noven Pharmaceuticals, Inc., Recent Developments 18
Noven Pharmaceuticals, Inc.- Press Release 18
Apr 03, 2013: Noven Pharma Confirms Filing Of ANDA For Generic Version Of Exelon 18
Mar 04, 2013: Noven Pharma Receives Negative Recommendation From FDA Panel For Low-Dose Mesylate Salt Of Paroxetine 18
Financial Deals Landscape 19
Noven Pharmaceuticals, Inc., Deals Summary 19
Noven Pharmaceuticals, Inc., Pharmaceuticals and Healthcare, Deal Details 20
Asset Transactions 20
Noven Pharma Acquires Rights To Minivelle From Novogyne Pharma 20
Noven Pharma Completes Acquisition Of Global Rights To Daytrana From Shire 21
Licensing Agreements 23
Noven Pharma Enters Into License Agreement With Procter and Gamble 23
Noven Pharma Enters Into Licenisng Agreement With Shire 24
Acquisition 25
Hisamitsu Pharma Completes Acquisition Of Noven Pharma 25
Noven Pharma Acquires JDS Pharma 27
Appendix 29
Methodology 29
Coverage 29
Secondary Research 29
Primary Research 29
Expert Panel Validation 29
Contact Us 30
Disclaimer 30



List of Tables

Noven Pharmaceuticals, Inc., Key Information 4
Noven Pharmaceuticals, Inc., Key Facts 4
Noven Pharmaceuticals, Inc. - Pipeline by Indication, 2013 6
Noven Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2013 7
Noven Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2013 8
Noven Pharmaceuticals, Inc. - Filed, 2013 9
Noven Pharmaceuticals, Inc. - Pre-Clinical, 2013 10
Noven Pharmaceuticals, Inc. - Pipeline By Route of Administration, 2013 13
Noven Pharmaceuticals, Inc. - Pipeline Products By Mechanism of Action, 2013 14
Noven Pharmaceuticals, Inc. - Recent Pipeline Updates, 2013 15
Noven Pharmaceuticals, Inc. - Dormant Developmental Projects,2013 16
Noven Pharmaceuticals, Inc., Other Locations 17
Noven Pharmaceuticals, Inc., Subsidiaries 17
Noven Pharmaceuticals, Inc., Deals Summary 19
Noven Pharma Acquires Rights To Minivelle From Novogyne Pharma 20
Noven Pharma Completes Acquisition Of Global Rights To Daytrana From Shire 21
Noven Pharma Enters Into License Agreement With Procter and Gamble 23
Noven Pharma Enters Into Licenisng Agreement With Shire 24
Hisamitsu Pharma Completes Acquisition Of Noven Pharma 25
Noven Pharma Acquires JDS Pharma 27



List of Figures

Noven Pharmaceuticals, Inc. - Pipeline by Indication, 2013 6
Noven Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2013 7
Noven Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2013 8

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Pipeline Review, H2 2016

Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • October 2016
  • by Global Markets Direct

Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Pipeline Review, ...

C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Pipeline Review, H2 2016

C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Pipeline Review, H2 2016’, ...

Huntingtin (Huntington Disease Protein or HTT) - Pipeline Review, H2 2016

Huntingtin (Huntington Disease Protein or HTT) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

Huntingtin (Huntington Disease Protein or HTT) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Huntingtin (Huntington Disease Protein or HTT) - Pipeline Review, H2 2016’, provides in ...


ref:plp2013

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.